Introduction
A primary goal of regenerative medicine is to produce new cells to repair or replace diseased and damaged tissues. Among the many innovative ideas proposed to achieve this goal, a particularly interesting one involves remaking existing adult cells into new ones by converting them from one cell type to another. For example, abundant human cells such as dermal fibroblasts and adipocytes could be harvested and converted into other, medically important cells such as neurons, cardiomyocytes, or pancreatic b cells. These new cells may then be transplanted back into the same patient. Remaking adult cells in this way has the advantage of providing a fully immunologically matched graft; the patient would be getting his or her own cells back. In short, this approach may be viewed as repurposing a piece of adult skin, for example, into part of the heart or pancreas.
Adult Cells Are Highly Stable
A clear challenge to remaking adult cells is that mature cells of adult organisms are remarkably stable. Differentiated cells maintain their state for years and rarely, if ever, switch to a new state. And indeed, switching or flip-flopping from one cell state to another would have dire consequences, including the formation of cancerous cell types. Cells arrive at a stable position by a progressive or sequential restriction in their options, beginning as a pluripotent embryonic cell and ending up at the mature differentiated state. Conrad H. Waddington, a pioneering embryologist, vividly depicts this process of cell differentiation as a ball rolling down valleys in an epigenetic landscape. The ball rolls downhill through bifurcated valleys of possible developmental paths, or ''chreodes'' as he called them, that lead to different cell types that can be realized (Waddington, 1957) . At the end, a cell finds itself at the bottom of a valley in a stable differentiated state ( Figure 1A) .
The ball (cell) at the end of the developmental process, at the bottom of the epigenetic landscape, is in a state often described as one of terminal differentiation. There are numerous lines of evidence suggesting that, once a cell has reached this state, it is permanent or nearly so; indeed, it is sometimes accompanied by the inability to divide any further, as in the case of red blood cells, keratinocytes, and many kinds of neurons. For those differentiated cells that do divide, of which there are many examples, a terminally differentiated cell produces daughters that are also fully differentiated. Many examples could be cited (Messier and Leblond, 1960; Tsubouchi et al., 1987) , and drawing from our own work, adult pancreatic b cells divide to give rise to new b cells, thereby providing a simple mechanism for organ maintenance (Dor et al., 2004) . Aside from aberrant cases observed in some cancers, the idea that adult cells are plastic, that they can switch fates from one cell type to another, has little observational or experimental support. There was a recent and brief period in the stem cell field where adult stem cell plasticity, essentially the opposite of stability, was being promoted based on the idea that certain adult stem cells were not restricted in their fates and could easily adopt new fates depending on their environment (reviewed by Weissman et al., 2001) . For example, it was suggested that blood stem cells could give rise to multiple lineages other than blood (Brazelton et al., 2000; Gussoni et al., 1999; Krause et al., 2001; Lagasse et al., 2000) . Despite initial indications that this might be possible, convincing evidence for the lack of plasticity in blood stem cells has been presented (Wagers and Weissman, 2004) . In other words, blood stem cells differentiate into blood, and neither they nor their daughters form other kinds of cells. To be more cautious, if plasticity in adult blood stem cells does occur, it does not appear to happen at an appreciable rate with any in vivo developmental or physiological significance. Thus, Waddington's epigenetic landscape is an apt description of cell differentiation, with an ever-increasing restriction in options culminating in a stable differentiated state.
Different Approaches to Convert Cells
The observations discussed above reflect on an understanding of what happens during normal development and the physiological maintenance of an adult. At the same time, it is, of course, important to appreciate the remarkable potential of cells, even terminally differentiated cells, as revealed by experimental manipulation. Pioneering experiments in amphibian in the 1960s, in particular those of Gurdon, revealed that the identity of a mature cell can be reversed and its daughter cells reconfigured by transplanting the nucleus of an adult cell into the cytoplasm of an unfertilized egg. Following nuclear transplantation, the differentiation process is reversed completely, and the adult cell's nucleus is returned to a pluripotent state from which it can go on and develop into an entire animal (Gurdon, 2006) . Following this striking demonstration using frog cells, reprogramming by somatic nuclear transfer (SCNT) has been accomplished in many mammalian species (Hochedlinger and Jaenisch, 2006) . These impressive demonstrations of the inherent potency of cells have led to a search for reprogramming factors that can directly convert differentiated cells back to a pluripotent stage. In one approach, this culminated in the discovery by Yamanaka and colleagues that adult skin cells can be induced to become pluripotent stem cells (iPSCs) in culture by a small set of transcription factors (Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Yu et al., 2007) . Both SCNT and iPSC reprogramming results in the formation of pluripotent stem cells, and for the purpose of this review, we refer to them collectively as pluripotent reprogramming. In Waddington's depiction, these reprogramming events would be equivalent to the ball (cell) rolling back up to the top of the hill to where it started ( Figure 1B) .
By completely reversing the developmental process, pluripotent reprogramming removes all or nearly all epigenetic marks laid down during development. The resulting cell type, a pluripotent stem cell, is not suitable for direct therapeutic applications. Instead, the stem cells must be differentiated in vitro into mature or progenitor cells such as neurons, cardiomyocytes, or osteoblasts, which can then be used in cellular therapies or drug screening. Directed differentiation of stem cells (embryonic stem cells or tissue-specific fetal and adult stem cells) is a very active area of research whose primary goal is to guide the fate choice of a multipotent cell toward a particular progeny. As such, it is a process that parallels normal development and does not involve the gain of additional potency. We therefore do not consider directed differentiation as a form of reprogramming and will not discuss it in detail in this essay.
Pluripotent reprogramming, followed by directed differentiation, offers a powerful strategy to regenerate any cell type in the body. Furthermore, this strategy is amicable for patient-specific therapies. Together, they form a very important part of the technological platform upon which regenerative medicine can be built.
In addition to pluripotent reprogramming, there are other reprogramming approaches that more directly convert mature cells to progenitors or other mature cells without going back to or through a pluripotent stage. For example, during salamander limb regeneration, adult skin, muscle, and cartilage cells dedifferentiate to a progenitor stage, which then redifferentiate to create a new limb (Brockes and Kumar, 2002) . After injury, pigmented epithelial cells of the iris form lens cells in a process called transdifferentiation (Eguchi and Okada, 1973) . Both dedifferentiation and transdifferentiation represent reprogramming strategies that do not involve reverting cells back to a pluripotent stage. In this way, many of the epigenetic marks of the starting cell types are preserved. In addition, the final cell types of these reprogramming processes, progenitors and mature cells, may be directly used in applications such as cell replacement therapies. We refer here to these approaches as lineage reprogramming (Orkin and Zon, 2008) (Figure 1C ), in distinction to pluripotent reprogramming.
There are yet other types of reprogramming events, for example, conversions between progenitor cells as in transdetermination (Hadorn, 1968) or certain types of metaplasia (Slack, 2007) . These reprogramming events, similar to lineage reprogramming, do not result in the formation of pluripotent stem cells and likely involve only partial alteration to the epigenetic marks. Thus, we include these reprogramming phenomena under lineage reprogramming.
Lineage reprogramming has long fascinated biologists in part because of the promise of harnessing this phenomenon for regenerative medicine whereby abundant adult cells could be converted directly into therapeutically important cell types for tissue repair and regeneration. Despite years of research, relatively little is known about how lineage reprogramming is accomplished. If one is to exploit this phenomenon to make new cells for therapeutic purposes, it would be important to know, for example, which genes and factors are sufficient to promote lineage reprogramming. In this regard, important insights come from studies on master regulator genes. For example, MyoD, a transcription factor critical in specifying the skeletal muscle lineage, can convert cultured embryonic fibroblast, chondroblast, and retinal epithelial cells into contracting muscle cells (Choi et al., 1990) . Similarly, B lymphocytes can be converted to macrophages by the transcription factor CEBP (Xie et al., 2004) , and inner ear support cells reprogrammed to hair cells by Math1 (Izumikawa et al., 2005; Zheng and Gao, 2000) . As significant as these studies are in emphasizing the power of master regulator genes in determining and converting cell lineages, they do not provide a general strategy for reprogramming differentiated cells.
A Broad Strategy for Adult Lineage Reprogramming
To formulate a broad strategy for lineage reprogramming, an important clue comes from regeneration, namely that the recreation of adult structures is preceded by reactivation of embryonic genes that normally function during organ development (Iovine, 2007; Slack et al., 2008; Tanaka, 2003) . This recapitulation of (B) During pluripotent reprogramming, which includes somatic cell nuclear transfer (SCNT) and formation of induced pluripotent stem (iPS) cells, the entire developmental process is reversed, and a differentiated cell is returned to a pluripotent state. This is represented by the ball (cell) rolling from the bottom of the valley backward all the way to the top. (C) Lineage reprogramming includes dedifferentiation and transdifferentiation, where a mature cell takes a step backward to a progenitor stage (cyan ball) or converts directly to another mature cell (yellow ball). Painting of the epigenetic landscape adapted from Waddington (1957) .
an embryonic genetic program suggests that expression of embryonic genes would be important for reprogramming adult cells, a hypothesis consistent with known examples of lineage reprogramming where the factors used are well-studied developmental regulators (Choi et al., 1990; Cobaleda et al., 2007; Kondo and Raff, 2000; Laiosa et al., 2006; Orkin and Zon, 2008; Xie et al., 2004; Zheng and Gao, 2000) .
With this principle in mind, our laboratory recently developed a strategy for adult lineage reprogramming and used it to directly convert mature pancreatic exocrine cells to endocrine b cells in adult animals . Both exocrine cells and b cells derive from embryonic pancreatic endoderm, yet they have distinct morphology and perform very different functions (Murtaugh, 2007) . To define the instructive reprogramming factors, we focused on transcription factors (TF), a class of genes particularly enriched in embryonic cell fate regulators. A genome-wide expression analysis of >1100 TFs on the developing pancreas revealed cohorts of TFs with specific expression in distinct progenitor cell types (Zhou et al., 2007) . About 30 TFs are expressed in pancreatic and endocrine progenitors, the two precursor cells that directly lead to the b cell lineage. Of these 30 genes, analysis of knockout studies pointed to 9/30 genes that appear to be required for b cell fate specification. Using an in vivo assay to test the nine candidate genes, we progressively eliminated individual factors from this gene pool and eventually identified just three factors that together reprogram adult exocrine cells to b cells .
Is this strategy likely applicable to other cell types? Decades of painstaking developmental studies have already detailed the lineages and regulator genes for many cell types. This rich knowledge, together with well-designed assays, should allow the reprogramming strategy used in our study to be broadly applied in other contexts. For example, there is a large body of knowledge about the lineages of neurons and their associated glial cells, and the genetic codes that govern their generation during embryogenesis are being elucidated (Hochstim et al., 2008; Jessell, 2000; Zhou and Anderson, 2002) . Similarly, the lineages and critical developmental factors for cardiomyocytes have become much better understood (Martin-Puig et al., 2008; Olson, 2004) , and there is an increasing volume of work being done to establish lineages for many other cell types. Taking the motor neuron as one example, this strategy would suggest that it may be possible to convert central nervous system glial cells into motor neurons, an attractive possibility in diseases of motor neuron deficiency such as Amyotrophic lateral sclerosis (ALS) or spinal cord injuries. And acute injuries such as heart attacks could be remedied by using cardiomyocytes reprogrammed from skeletal muscle or skin fibroblasts. Whether such optimistic prediction can be realized should become clear in the next few years. Cell types such as motor neurons and cardiomyocytes could also be derived with other approaches, such as directed differentiation from embryonic stem cells or differentiation from fetal or adult progenitor cells. It remains to be seen which one of these approaches will eventually yield therapeutically useful cells.
It is prudent to be cautious about interpreting a change in gene expression as lineage reprogramming or cell type conversion. For example, some reported cellular ''conversions'' are achieved by ectopic expression of powerful transcription factors that are capable of direct binding to gene promoters and forcing expression of, for example, the insulin or muscle actin gene. Constitutive expression of multiple such factors can force a specific transcription program onto the host cell without stable cell type conversion. A true lineage reprogramming event is most useful if it requires only a transient expression of the reprogramming factors, and the resulting cell should make a full phenotypic switch without exhibiting a hybrid phenotype. In this context, we note that cell fusion can produce heterokaryons with a hybrid or mixed phenotype. A further consideration is that cells converted in vitro, where cellular morphology and physiology are prone to change, would ideally be further tested for their stability and function by transplantation for in vivo analysis.
In principle, an adult cell may be reprogrammed into another mature cell or a progenitor/stem cell with the lineage reprogramming strategy. For example, a pancreatic exocrine cell may be converted to a b cell, or an endocrine progenitor that produces all pancreatic endocrine cell types. Likewise, an astroglia in the nervous system may be converted directly to a neuron, or instead to a neural stem cell that produces all neural cell types. To define the reprogramming factors for the different ''end'' cell types, two central questions stand out. First, what genes are good candidate factors to test? And second, should the test be carried out in vivo or in vitro?
While each lineage reprogramming experiment must be designed in a case-by-case manner, some general guidelines may be suggested. For example, important developmental regulator genes expressed in the lineage of the final cell type are good candidates for reprogramming factors. The best candidates would be those that exhibit clear knockout phenotypes, where deletion of the gene results in severe developmental defects or complete absence of the particular cell type. Lineage analysis, by determining precisely which cells express the candidate gene and at what times during development, is also very instructive. If knockout studies and lineage analyses are not available, gene expression data could be used to point to selected gene families such as transcription factors of the homeobox and bHLH families, and extracellular factors such as Wnt and Notch families, which often play important roles in development. Emphasis should be placed on selecting candidate factors from progenitors or immature cells, rather than focusing solely on fully differentiated cells. This selection criterion is supported by known examples of lineage reprogramming where the reprogramming factors, such as MyoD, Ngn3, and Math1, have expression in immature rather than mature cells.
Once a list of candidate reprogramming factors is selected, they can be tested in vivo or in vitro. An in vitro culture system offers the advantage of controlled conditions where large numbers of factors can be tested in parallel. This approach, however, depends on the availability of optimized culture conditions which, for many cell types, are still lacking. Alternatively, candidate factors can be tested directly in vivo, as done in the b cell reprogramming study . Experiments in living animals are more demanding, and only a small number of factors may be tested. In addition, it is currently unclear how much influence the cells' native environment, including interactions with their neighboring cells, has in ''stabilizing'' the starting cell population and thereby making the in vivo conversion more difficult. Furthermore, it is unknown whether reprogramming factors defined in culture conditions would be sufficient to reprogram cells directly in vivo.
Role of the Niche
For cellular conversions that occur in vivo, the role of the cellular environment, or niche, should be considered. The differentiated state of a mature cell is most stable when the cell resides in its native environment, for example, a neuron in the nervous system. When ectopically induced in a different organ system, a mature cell may exhibit altered phenotype or function. It may therefore be advantageous to induce mature cells directly in their native tissue environment during in vivo reprogramming.
Compared to mature cells, progenitors and stem cells may have even more stringent requirements for their niches (Fuchs et al., 2004; Jones and Wagers, 2008) . If there are suitable culture conditions for the progenitor/stem cells, then the experiment can be carried out in vitro, as in the case of converting oligodendrocyte progenitors to neural stem cells (Kondo and Raff, 2000) . If the reprogramming is performed directly in vivo, however, an environmental niche must be available. Otherwise, even if the conversion is successful, the resulting progenitor/ stem cell may immediately undergo apoptosis or differentiation. Perhaps due to this reason, there have been very few reports of in vivo reprogramming in adult that produce progenitor/stem cells. Deletion of Pax5 leads to conversion of mature B lymphocytes to uncommitted hematopoietic progenitors in adult animals (Cobaleda et al., 2007) . This success is likely aided by the fact that circulating blood cells have ready access to existing niche environments (lymph nodes, in this particular example). Nevertheless, an in vivo strategy should be possible for any tissue that harbors adult progenitor/stem cells such as the hematopoietic system, the nervous system, skeletal muscle, skin, and others.
Strategies that May Facilitate Adult Lineage Reprogramming
Current examples of lineage reprogramming have primarily relied on ectopic expression of reprogramming factors. These factors must establish a new epigenetic program in the host cell and erase the original program. There is evidence suggesting that deletion of factors that support the original epigenetic state of host cells can facilitate their phenotypic conversion. As discussed above, deletion of Pax5, a factor critical in establishing B cell identity, allows conversion of B lymphocyte to uncommitted hematopoietic progenitors (Cobaleda et al., 2007) . Removal of Polycomb and Trithorax epigenetic factors also facilitates legto-wing transdetermination in fly (Klebes et al., 2005) . These studies suggest that a reprogramming strategy that couples ectopic expression of reprogramming factors with a simultaneous reduction of host cell maintenance factors may be most efficient ( Figure 2B ). The example of B cell dedifferentiation further suggests that, in some cases, removal of host cell maintenance factors by itself might be sufficient to convert cells ( Figure 2B ). The deletion/knockdown-based strategy may be particularly important for dedifferentiation efforts aimed at generating progenitor or tissue-specific stem cells from mature cells, which are believed to possess factors that are dedicated to maintaining the differentiated state. The identity of such maintenance factors, however, remains largely unknown.
In addition to improving the chances of success of achieving lineage reprogramming by ''loosening'' the maintenance factors that define a terminal state, some cell types might be more amenable to reprogramming toward a given target lineage than others. That is, to generate a given cell type through lineage reprogramming, different starting cell populations may be used. For example, to produce pancreatic b cells, pancreatic exocrine or duct cells may serve as the starting points, or perhaps liver cells, a closely related endoderm cell type, may be used. One could even stretch this idea to skin fibroblasts, the product of a different germ layer, for a starting population. The ease of converting these different cell types to b cells, however, will likely be S2) give rise to progenitor cells (P1-P3), which generate different mature cell types (M1-M7). In both transdifferentiation and dedifferentiation, different start cell types may be reprogrammed to the same final cell type. In principle, a closely related cell type should be easier to convert (dark arrow) than a more distantly related cell type (light arrow). (B) Reprogramming of one cell (orange) to another (pink) may be achieved by ectopic expression of factors (green star) or deletion/knockdown of factors (black X), or both. Reagents that loosen chromatin structures or enhance proliferation are predicted to enhance cell type conversions. The factors and reagents used may be genes, siRNA, or chemical compounds.
quite different. Distinct cell types are defined by their unique combination of epigenetic marks that are accumulated progressively during the numerous developmental steps. Closely related cell types, such as the pancreatic exocrine cell and b cell, share much of their developmental history and therefore also share much of their epigenetic makeup, or epigenome (Bernstein et al., 2007) . This epigenetic similarity should make it easier to interconvert these two cell types, as only a small portion of their epigenomes would have to be rearranged. More distantly related cells have more epigenetic differences, including DNA and histone modifications, which can make chromosomal regions relatively inaccessible and difficult to unravel. Thus, to produce a particular cell type by lineage reprogramming, it may be desirable to choose a starting cell type that is closely related to the final cell (Figure 2A ).
There will be cases, however, where it is not possible or convenient to obtain a closely related starting population, in which case, several additional measures may be helpful. For example, chemicals, such as HDAC inhibitors, may be used to ''loosen'' chromatin structures (Xu et al., 2008) . In addition, cells are thought to be most vulnerable to epigenetic change at mitosis, when chromosomes decondense and the nuclear envelope breaks down, allowing easier access to the chromosomes for reprogramming factors (Hochedlinger and Jaenisch, 2006) . Stimulating cell proliferation may therefore facilitate cell type conversions ( Figure 2B ).
It is notable that current examples of lineage reprogramming mostly occur between closely related cell types (Choi et al., 1990; Cobaleda et al., 2007; Kondo and Raff, 2000; Laiosa et al., 2006; Orkin and Zon, 2008; Xie et al., 2004; Zheng and Gao, 2000) . Even with the additional facilitating measures as discussed above, it is unclear whether distantly related cell types can indeed be fully converted with a lineage reprogramming approach.
Comparing the Main Reprogramming Approaches
Recent advances in lineage reprogramming promise the development of powerful alternative regeneration strategies based on transdifferentiation and dedifferentiation that will complement pluripotent reprogramming and iPSC technology. The two major reprogramming approaches differ in several important aspects (Table 1) . For example, factors that direct pluripotent reprogramming have already been discovered, and these factors appear capable of reprogramming a wide variety of cell types to stem cells (Aoi et al., 2008; Hanna et al., 2008; Kim et al., 2008; Stadtfeld et al., 2008) . In contrast, lineage reprogramming factors are likely to be specific for each cell type, and most of the instructive factors remain undefined. On the other hand, the final products of lineage reprogramming, such as progenitor cells and mature cells, are suitable for direct clinical applications, whereas the final product of pluripotent reprogramming, ESCs and iPSCs, depend on directed differentiation to convert them to mature or progenitor cells.
An advantage of lineage reprogramming is the possibility of converting cells directly in vivo for in situ regeneration and repair. For example, pancreatic exocrine cells reprogrammed into b cells may be induced to join existing islets to replenish b cells that were destroyed by autoimmune attacks in type 1 diabetes. Or neurons converted from glial cells could join existing neuronal networks to repair specific nervous system damages, as in Parkinson's disease or spinal cord injury. These in vivo repair and regeneration strategies are not possible with iPSC-based reprogramming approaches, if for no other reason than the fact that iPSCs would form teratomas in vivo (Table 1) .
Another potential advantage of lineage reprogramming approaches is the possibility that by taking one step back, or a step sideways, only part of the numerous epigenetic marks established during development need be reset or rearranged. In contrast, iPSC generation necessitates the removal of nearly all epigenetic marks, and these would need to be correctly reestablished during in vitro differentiation of iPSCs (Table 1) .
A potential limitation of the lineage reprogramming approach is that it may be most suitable for closely related cell types. At present, it is unclear whether distantly related cell types can be fully converted with lineage reprogramming. Pluripotent reprogramming, together with directed differentiation, should be able to produce all cell types in the body.
ESCs and iPSCs have nearly unlimited capacity to proliferate in culture. On one hand, this provides abundant starting material to produce desired cell types. On the other, the many cycles of proliferation required in the derivation of iPSCs and their subsequent differentiation may select for fast-growing, culture-adapted cells that harbor subtle genetic mutations. Such changes could result in unstable phenotypes, including cancer, when cells are transplanted in vivo. Lineage reprogramming, particularly between closely related cell types, should require fewer proliferation steps and thus may reduce the chance of mutations (Table 1) .
Remaining Challenges for Lineage Reprogramming
In terms of developing patient-specific therapies, reprogramming mature cells from patients, rather than immature cells from embryos, may be the most practical approach. However, the terminal differentiation steps that create mature cells are (Orkin and Zon, 2008) . In addition, it has been shown that mature cells are more difficult to be reprogrammed into a pluripotent state than immature cells (Blelloch et al., 2006; Hanna et al., 2008) . Currently, rather little is known about the epigenetic programs that are specifically activated during terminal differentiation, and there is reason to believe that a better understanding of these mechanisms would allow for the design of better strategies to reprogram mature cells. At this time, efforts of lineage reprogramming are largely focused on identifying effective reprogramming factors, which will likely vary depending on each target and final cell type. This is, of course, only the first step, and hopefully more will soon be learned about the molecular basis for the reported lineage reprogramming events (Choi et al., 1990; Cobaleda et al., 2007; Kondo and Raff, 2000; Laiosa et al., 2006; Orkin and Zon, 2008; Xie et al., 2004; Zheng and Gao, 2000) . Lineage reprogramming strategies have been employed to treat diseases in animal models. For example, inner ear hair cells converted from support cells improve the hearing of deaf animals (Izumikawa et al., 2005) , whereas b cells converted from pancreatic exocrine cells can ameliorate hyperglycemic conditions . Significant challenges remain, however, to translate these and other lineage reprogramming approaches to clinical applications in humans. To list just a few, protein-based reprogramming factors, such as transcription factors, will have to be replaced by safer alternatives such as small molecules; potential risk factors, such as partially reprogrammed cells that may be prone to malignant transformations, must be properly addressed; and the reprogrammed cells may need to be organized into tissues or even organs before clinical use.
The last decade has seen an explosion of interest in regenerative medicine. Many strategies are being pursued to generate clinically useful new cells. These strategies include the identification and differentiation of fetal and adult stem/progenitor cells and the generation and directed differentiation of ESCs and iPSCs, among others. Significant progress has been made on these fronts. Although the phenomena of lineage reprogramming have long been known, systematic studies on the feasibility of exploiting lineage reprogramming for regenerative medicine have just begun. Despite the many challenges that lay ahead, we are optimistic that lineage reprogramming offers an attractive approach with distinct advantages to become an important part of the future of regenerative medicine.
